RE:RE:RE:RE:RE:Takeda acquiring Nimbus Therapeutics subsid for US$4 BillionYesterday Nimbus Lakshimi (a subsidiary of Nimbus LLC.) was valued at $ "0" (zero) ... and today it was acquired by Japan's Takeda for US$ 4 Billion in cash + US$2 Billion in commercial milestones for a total of US$6 Billion.
So if Nimbus Lakshimi went from $US 0.00 to US$6.0 Billion (all-in one day) then ONCY's immune molecule platform pelareorep is worth at least US$ 12 Billion in an all cash up-front deal.